Yoon Eunchae, Shin Chaewon, Bae Hyeona, Cho Kyu-Woan, Jung Dong-In, Park Jinho, Lee Dongbin, Yu DoHyeon
College of Veterinary Medicine, Gyeongsang National University, Jinju, Republic of Korea.
College of Veterinary Medicine, Jeonbuk National University, Iksan, Republic of Korea.
Front Vet Sci. 2025 Jun 5;12:1555641. doi: 10.3389/fvets.2025.1555641. eCollection 2025.
Clopidogrel is frequently used in veterinary medicine to therapeutically decrease platelet function, although some different dosages have been published. Therefore, we assessed the antiplatelet effects of the recommended dosage (1 mg/kg PO q24h) on canine platelet function.
Five dogs were administered either clopidogrel or placebo, with a 14-day washout period. Platelet function was assessed using thromboelastography (TEG) and flow cytometry, complete blood count, and biochemical analyses were performed for clinicopathological evaluation. Blood samples were collected at baseline and 7 days after drug administration. TEG parameters including maximum amplitude and platelet mapping for adenosine diphosphate (ADP)-induced responses were used to monitor therapeutic efficacy. Flow cytometry was used to analyze CD62P expression and platelet activation stimulated by ADP and other agonists.
TEG analysis demonstrated a significant reduction in ADP-induced clot strength following clopidogrel administration ( < 0.05), indicating effective platelet inhibition. Flow cytometry confirmed the marked inhibition of platelet activation, with significant decreases in the percentage of CD62P positive platelets and the mean fluorescence intensity under ADP and epinephrine stimulation ( < 0.05). Hematological and biochemical parameters remained stable across all groups, confirming the safety of clopidogrel administration. These findings highlight the efficacy and safety of clopidogrel as an antiplatelet agent in dogs.
This study confirmed the efficacy of low-dose (1 mg/kg, p.o., q24h) clopidogrel in dogs without a loading dose. TEG and flow cytometry are effective tools for assessing clopidogrel responsiveness in dogs and may aid in optimizing antiplatelet therapy in clinical practice.
氯吡格雷在兽医学中常用于治疗性降低血小板功能，尽管已发表了一些不同的剂量。因此，我们评估了推荐剂量（1毫克/千克口服，每24小时一次）对犬血小板功能的抗血小板作用。
五只犬接受氯吡格雷或安慰剂治疗，有14天的洗脱期。使用血栓弹力图（TEG）和流式细胞术评估血小板功能，并进行全血细胞计数和生化分析以进行临床病理评估。在基线和给药后7天采集血样。TEG参数包括最大振幅和二磷酸腺苷（ADP）诱导反应的血小板图，用于监测治疗效果。流式细胞术用于分析ADP和其他激动剂刺激后的CD62P表达和血小板活化情况。
TEG分析表明，给予氯吡格雷后，ADP诱导的血凝强度显著降低（<0.05），表明血小板得到有效抑制。流式细胞术证实血小板活化受到显著抑制，在ADP和肾上腺素刺激下，CD62P阳性血小板百分比和平均荧光强度显著降低（<0.05）。所有组的血液学和生化参数均保持稳定，证实了氯吡格雷给药的安全性。这些发现突出了氯吡格雷作为犬抗血小板药物的有效性和安全性。
本研究证实了低剂量（1毫克/千克，口服，每24小时一次）氯吡格雷在犬中无需负荷剂量的有效性。TEG和流式细胞术是评估犬对氯吡格雷反应性的有效工具，可能有助于优化临床实践中的抗血小板治疗。
